SCHEMBL422382

SCHEMBL422382

O=c1cccnn1-c1ccc2nc3n(c2c1)CCN(C1CCC1)CC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.41
MAPT P10636 6/20 0.36
ALDH1A1 P00352 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 6/20 0.35
GAA P10253 2/20 0.35
KCNH2 Q12809 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7890370 0.93 MAPT (0.43) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL417681 0.82 HRH3 (0.53) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL418406 0.81 MAPK8 (0.37) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL421387 0.81 ALDH1A1 (0.40) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL421170 0.80 ALDH1A1 (0.42) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL422383 0.78 HRH3 (0.34) HRH3RAB9AKCNH2CA12CA1
SCHEMBL418547 0.77 KDM2B (0.35) HRH3MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL418330 0.77 CHRM1 (0.44) MAPTOPRM1OPRD1OPRK1OGFRL1
SCHEMBL420032 0.76 PGR (0.43) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL422484 0.76 KDM4E (0.42) HRH3MAPTALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 US disclosed
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2012-01-26 US disclosed
US-8063032-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-11-22 US disclosed
US-20100204214-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204214-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAPT 738/4885ALDH1A1 2598/4885
US-20120022050-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF HRH3, HRH4, HRH2 HRH3 1/4885MAPT 738/4885ALDH1A1 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.